Abstract:The human microbiota is fundamental to correct immune system development and balance. Dysbiosis, or microbial content alteration in the gut and respiratory tract, is associated with immune system dysfunction and lung disease development. The microbiota's influence on human health and disease is exerted through the abundance of metabolites produced by resident microorganisms, where short-chain fatty acids (SCFAs) represent the fundamental class. SCFAs are mainly produced by the gut microbiota through anaerobic fermentation of dietary fibers, and are known to influence the homeostasis, susceptibility to and outcome of many lung diseases. This article explores the microbial species found in healthy human gastrointestinal and respiratory tracts. We investigate factors contributing to dysbiosis in lung illness, and the gut-lung axis and its association with lung diseases, with a particular focus on the functions and mechanistic roles of SCFAs in these processes. The key focus of this review is a discussion of the main metabolites of the intestinal microbiota that contribute to host-pathogen interactions: SCFAs, which are formed by anaerobic fermentation. These metabolites include propionate, acetate, and butyrate, and are crucial for the preservation of immune homeostasis. Evidence suggests that SCFAs prevent infections by directly affecting host immune signaling. This review covers the various and intricate ways through which SCFAs affect the immune system's response to infections, with a focus on pulmonary diseases including chronic obstructive pulmonary diseases, asthma, lung cystic fibrosis, and tuberculosis. The findings reviewed suggest that the immunological state of the lung may be indirectly influenced by elements produced by the gut microbiota. SCFAs represent valuable potential therapeutic candidates in this context.

Gut-Derived Short-Chain Fatty Acids and Macrophage Modulation: Exploring Therapeutic Potentials in Pulmonary Fungal Infections

A Metabolite from Commensal Candida Albicans Enhances the Bactericidal Activity of Macrophages and Protects Against Sepsis

Bacteria-derived short-chain fatty acids as potential regulators of fungal commensalism and pathogenesis

Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases

Short-chain fatty acids as a potential treatment for infections: a closer look at the lungs

Short‐chain fatty acids: bridges between diet, gut microbiota, and health

Short-chain fatty acids in viral infection: the underlying mechanisms, opportunities, and challenges

Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism

Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis—A Potential Therapeutic Intervention to Improve Lung Health

A major mechanism for immunomodulation: Dietary fibres and acid metabolites

Short-chain fatty acids in diseases

Lung microbiota and potential treatment of respiratory diseases

Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease

Microbiota-Derived Short-Chain Fatty Acids Promote LAMTOR2-Mediated Immune Responses in Macrophages

The role of lipids in regulating macrophage antifungal immunity

Macrophage Mediated Immunomodulation During Cryptococcus Pulmonary Infection

Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease

Short-chain fatty acids: linking diet, the microbiome and immunity

Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus on Aspergillus spp.

Short-Chain Fatty Acid and FFAR2 Activation - A New Option for Treating Infections?